Forbes1y
VA Will Cover Alzheimer’s Disease Drug Lecanemab, Provided A Detailed Set Of Inclusion And Exclusion Criteria Are Met
At the same time, VHA has issued a list of conditions of reimbursement that are consistent with but also go well beyond the Food and Drug Administration (FDA) label for lecanemab when it was ...
Morningstar15d
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
Results from the open-label long-term extension study (OLE) following the core study of the lecanemab phase 3 Clarity AD study presented at AAIC in July, showed that the mean change from baseline ...
Nasdaq15d
Biogen/Eisai announce latest findings for Leqembi in Alzheimer’s disease
In July 2024 at the Alzheimer’s Association International Conference 2024, results from the open-label long-term extension study (OLE) following the core study of the lecanemab Phase 3 Clarity ...